Compare
Pulse Biosciences, Inc. vs Family Office of America, Inc. vs Co-Diagnostics, Inc. vs Harvard Apparatus Regenerative Technology, Inc.
| Latest fiscal year | Pulse Biosciences, Inc. PLSE | Family Office of America, Inc. FOFA | Co-Diagnostics, Inc. CODX | Harvard Apparatus Regenerative Technology, Inc. HRGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $350.0K | $221.8K | $622.5K | $704.0K |
| Revenue growth (YoY) | n/a | n/a | -84.1% | +63.7% |
| Gross margin | -54.0% (computed) | 100.0% | 64.3% | n/a |
| Operating margin | n/m | -226.0% | n/m | -982.2% |
| Net margin | n/m | -222.2% | n/m | -975.7% |
| Net income | -$72.78M | -$492.7K | -$46.90M | -$6.87M |
| EPS (Diluted) | n/a | -$0.02 | -$35.25 | n/a |
| Operating cash flow | -$54.12M | -$262.2K | -$29.14M | -$3.83M |
| Free cash flow | -$54.44M | n/a | -$29.84M | n/a |
| Cash & equivalents | $80.73M | n/a | $11.88M | $1.35M |
| Total assets | $94.54M | $1.54M | $24.74M | $2.68M |
| Total liabilities | $13.88M | $878.5K | $4.11M | $1.62M |
| Shareholders' equity | $80.66M | $664.5K | $20.63M | $1.06M |
| Return on year-end equity | -90.2% | -74.2% | -227.3% | -649.9% |
| Shares outstanding | 67.84M | 30.20M | 2.10M | 17.58M |
Revenue, most recent five fiscal years
| Fiscal year | Pulse Biosciences, Inc. | Family Office of America, Inc. | Co-Diagnostics, Inc. | Harvard Apparatus Regenerative Technology, Inc. |
|---|---|---|---|---|
| Latest | $350.0K Ended 2025-12-31 | $221.8K Ended 2025-12-31 | $622.5K Ended 2025-12-31 | $704.0K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | n/a | $3.92M Ended 2024-12-31 | $430.0K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | n/a | $6.81M Ended 2023-12-31 | $103.0K Ended 2023-12-31 |
| 3 years earlier | $700.0K Ended 2022-12-31 | n/a | $34.22M Ended 2022-12-31 | n/a |
| 4 years earlier | $1.42M Ended 2021-12-31 | n/a | $97.89M Ended 2021-12-31 | n/a |